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Abstract
Background: Alterations to pulmonary surfactant composition have been encountered in the
Acute Respiratory Distress Syndrome (ARDS). However, only few data are available regarding the
time-course and duration of surfactant changes in ARDS patients, although this information may
largely influence the optimum design of clinical trials addressing surfactant replacement therapy.
We therefore examined the time-course of surfactant changes in 15 patients with direct ARDS
(pneumonia, aspiration) over the first 8 days after onset of mechanical ventilation.
Methods:  Three consecutive bronchoalveolar lavages (BAL) were performed shortly after
intubation (T0), and four days (T1) and eight days (T2) after intubation. Fifteen healthy volunteers
served as controls. Phospholipid-to-protein ratio in BAL fluids, phospholipid class profiles,
phosphatidylcholine (PC) molecular species, surfactant proteins (SP)-A, -B, -C, -D, and relative
content and surface tension properties of large surfactant aggregates (LA) were assessed.
Results: At T0, a severe and highly significant reduction in SP-A, SP-B and SP-C, the LA fraction,
PC and phosphatidylglycerol (PG) percentages, and dipalmitoylation of PC (DPPC) was
encountered. Surface activity of the LA fraction was greatly impaired. Over time, significant
improvements were encountered especially in view of LA content, DPPC, PG and SP-A, but
minimum surface tension of LA was not fully restored (15 mN/m at T2). A highly significant
correlation was observed between PaO2/FiO2 and minimum surface tension (r = -0.83; p < 0.001),
SP-C (r = 0.64; p < 0.001), and DPPC (r = 0.59; p = 0.003). Outcome analysis revealed that non-
survivors had even more unfavourable surfactant properties as compared to survivors.
Conclusion: We concluded that a profound impairment of pulmonary surfactant composition and
function occurs in the very early stage of the disease and only gradually resolves over time. These
observations may explain why former surfactant replacement studies with a short treatment
duration failed to improve outcome and may help to establish optimal composition and duration of
surfactant administration in future surfactant replacement studies in acute lung injury.
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Background
Pulmonary surfactant, which covers the large alveolar sur-
face in all mammalian species investigated, is composed
primarily of phospholipids (80–85%), with dipalmi-
toylated phosphatidylcholine (DPPC) predominating
(~50% of all PC species). It also contains neutral lipids
(10%) and surfactant-specific proteins (SP-A, SP-B, SP-C,
SP-D; together 5–10%) [1,2]. By reducing alveolar surface
tension, pulmonary surfactant stabilizes the alveoli and
prevents them from collapse. Alterations to the pulmo-
nary surfactant system have long been implicated in the
course of inflammatory lung diseases such as the Acute
Respiratory Distress Syndrome (ARDS). Indeed, in clinical
studies focusing on ARDS [3-6] and, more recently, on
severe pneumonia [6], a marked impairment of surface
activity of surfactant isolates from BALF has been docu-
mented. To date, most attention has been focused on the
analysis of the phospholipid profiles and the apoprotein
content of surfactant from patients with ARDS. SP-A [5,6],
SP-B [5,6] and SP-C levels [7] were decreased, the relative
phosphatidylcholine palmitic acid content was reduced
[3,8], and a marked reduction in phosphatidylglycerol
(PG) has been observed throughout. In addition, the
inhibitory action of fibrin(ogen) [9] and other plasma
proteins [10] entering the alveolar space, proteases [11],
phospholipases [12] and reactive oxygen species [13] on
surfactant function has been described.
Despite advances in the field of intensive care medicine,
ARDS is still characterized by high mortality rates (30–
40%) and the only successful medical intervention that
significantly reduces mortality is a protective lung ventila-
tion strategy [14]. Pharmacological interventions,
although assessed in numerous clinical studies, have all
failed to exert a significant influence on outcome [15]. In
view of transbronchial surfactant application, recent stud-
ies revealed that it is possible to beneficially affect gas
exchange in patients with early ARDS if the appropriate
material and dose is applied [16-19]. Pulmonary shunt
flow, the predominant gas exchange abnormality in ARDS
patients, is largely reduced upon transbronchial applica-
tion of 300 mg/kg body weight of a natural surfactant
preparation (Alveofact®) in ARDS patients, alongside with
a significant improvement in surface activity of the alveo-
lar surfactant pool [20,21]. Similarly, improvement of gas
exchange has been encountered in two large phase III
studies assessing the efficacy of a recombinant SP-C based
surfactant preparation (Venticute®) in early ARDS subjects
[17,22]. In these patients, surfactant was administered up
to four times within a treatment window of 24 h. Despite
the beneficial effect on gas exchange throughout this treat-
ment window, duration of mechanical ventilation and
outcome remained unaffected by Venticute® treatment.
Two possible explanations exist for the observed failure of
Venticute®  treatment to improve outcome in these
patients: i) the profound impact of non-pulmonary organ
failure on outcome in indirect forms of ARDS (pancreati-
tis, trauma, non-pulmonary sepsis) and ii) the potentially
short duration of treatment (first 24 h after inclusion).
Indeed, robust data on the time-course of surfactant
changes in acute inflammatory lung diseases are limited,
either due to the time period investigated in observational
studies, or to the restricted number of parameters ana-
lyzed [4,23,24]. However, data regarding the time-course
and duration of surfactant alterations in ARDS patients
may help to understand why surfactant replacement stud-
ies with a short treatment duration failed to improve out-
come and may help to determine the optimal timing and
duration of exogenous surfactant administration and the
optimal composition of the exogenous surfactant mate-
rial. We, therefore, analyzed biochemical and biophysical
surfactant properties in 15 patients with direct ARDS at
three different time points over an observation period of
8 days after onset of mechanical ventilation (< 24 h, ~4
days and ~8 days).
Methods
Patient Population
Patients were recruited at the intensive care unit of the
Department of Internal Medicine of the Justus-Liebig-Uni-
versity in Giessen, Germany between 1999 and 2002. The
study protocol was approved by the local ethics commit-
tee, and informed consent was obtained from either the
patient or next of kin.
15 German patients with direct ARDS due to pneumonia
(n = 13) or aspiration (n = 2) were included. All patients
are of caucasian origin. The inclusion criteria included:
age between 18 and 70 years; diagnosis of ARDS accord-
ing to the Consensus Conference Criteria [25] due to aspi-
ration (if witnessed) or pneumonia (if one major (cough,
sputum production, fever) and two minor (dyspnea, pleu-
ritic chest pain, altered mental status, pulmonary consoli-
dation by physical examination, total leukocyte count >
12000/mm3) criteria were fulfilled) [26].
Exclusion criteria included the following: pregnancy,
acute myocardial infarction, left heart failure (pulmonary
capillary wedge pressure > 18 mm Hg as assessed by a pul-
monary-artery catheter or missing evidence in echocardi-
ography), lung contusion, any preexisting lung disease
(e.g. fibrosis, chronic obstructive lung disease) with a
FEV1 or FVC ≤ 65% predicted, malignant underlying dis-
ease including primary cancer of the lung or cancer meta-
static to the lung, immunosuppressive drugs and
leukopenia (white blood cells < 1000/µl), severe trau-
matic or hypoxic brain injury, additional investigational
drugs.Respiratory Research 2007, 8:55 http://respiratory-research.com/content/8/1/55
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All patients required mechanical ventilation. Respirator
settings were chosen according to the individual require-
ments. General therapeutic approaches included intrave-
nous volume substitution, low-dose heparin application,
parenteral nutrition, antibiotic drug therapy, and admin-
istration of vasoactive or inotropic drugs, when indicated.
The main demographic and clinical data of the patient
group are summarized in Table 1.
The control group consisted of 15 spontaneously breath-
ing healthy German volunteers, all never smokers, with
normal pulmonary function and without any history of
cardiac or lung disease (medical staff from the Depart-
ment of Internal Medicine or medical students from the
Medical School of the Justus-Liebig University Giessen,
Germany). All controls underwent a detailed medical,
drug and tobacco history, a physical examination, an elec-
trocardiogram, clinical laboratory tests (hematology, clin-
ical chemistry, coagulation), and pulmonary function
prior to inclusion into the study.
Study design and bronchoscopy
It was predefined that patients would have to undergo
three repetitive BALs, the first within 24 h after intubation
(T0), the second between four and five days, and the last
one between seven and nine days (T2) after intubation.
The average time from diagnosis of ARDS to initial BAL
was 21 ± 2 hours. Patients that were originally included
into the study but dropped out later either due to extuba-
tion (n = 2) or death (n = 4) were excluded from data anal-
ysis.
Flexible fiberoptic bronchoscopy was performed in
patients and controls by one physician in a standardized
manner as previously described [6]. The first BAL was per-
formed in the middle lobe or lingua, the second in the
respective contralateral segment and the third in the same
segment as the first. A lavage volume of 200 ml of sterile
normal saline in ten equal aliquots was used. The recov-
ered bronchoalveolar lavage fluid (BALF) was pooled, fil-
tered through sterile gauze, and immediately centrifuged
(300 × g, 10 min, 4°C) to remove cells and membraneous
debris. The aliquoted supernatant was subsequently fro-
zen and kept at -80°C until further use. Sedimented BALF
cells were resuspended in saline solution, counted and
subjected to a cyto spin maneuver [27]. Staining was per-
formed according to the Papenheim method (2 min in
Table 1: Clinical and basic BALF data and cell counts§
ARDS Control
T0 (<24 h) T1 (3–5 d) T2 (7–9 d)
Time point of BAL 12.1 ± 1.3 hours 3.9 ± 0.6 days 8.1 ± 1.0 days
Number of subjects 15 15 15 15
Age [years] 52.1 ± 3.7 *** 30.8 ± 3.2
Sex f/m 7/8 9/6
Current smoker [n] 1
Ex smoker [n] 5
Never smoker [n] 9
Ethnic origin:
Caucasian 15
PaO2/FiO2 [mm Hg] 127.8 ± 10.5 *** 129.1 ± 9.9 200.7 ± 24.1 § 511.1 ± 23.2
PEEP [cm H2O] 8.4 ± 0.8 8.4 ± 0.7 7.4 ± 0.7
Tidal Volume [ml/kg bw] 9.4 ± 0.8 9.0 ± 0.6 8.9 ± 0.6
PIP [cm H2O] 24.9 ± 1.3 25.8 ± 1.5 26.3 ± 1.9
APACHE II score 19.2 ± 2.2 21.5 ± 2.0 19.3 ± 1.8
Patients alive day 28 [n]/% 9/60%
Time of ventilation [d] 40.9 ± 10.8
Ventilator-free days at day 28 [d] 1.6 ± 1.4
Recovery BALF [%] 61.1 ± 3.6 *** 55.9 ± 4.6 65.1 ± 4.6 82.0 ± 2.0
Neutrophils [%] 60.8 ± 6.5 *** 47.5 ± 8.8 § 23.0 ± 7.3 §§§ 0.8 ± 0.2
Lymphocytes [%] 7.2 ± 5.1 7.7 ± 4.3 7.6 ± 3.1 4.4 ± 0.8
Macrophages [%] 32.0 ± 5.2 *** 44.8 ± 8.1 § 69.4 ± 7.1 §§§ 94.8 ± 0.8
Total protein [µg/ml] 1139 ± 240 *** 886 ± 167 384 ± 85 §§§ 76 ± 8
§ All data are given as mean ± standard error. PaO2/FiO2 = mean oxygen tension in arterial blood/inspiratory oxygen fraction. PEEP = positive end-
expiratory pressure. PIP = peak inspiratory pressure. APACHE II = scores on the acute physiology and chronic health evaluation. Cell counts and 
total proteins were measured in BALF. Tidal volume is expressed per ideal body weight. Control = healthy volunteers; ARDS = Acute respiratory 
distress syndrome. *** = p < 0.001: T0 compared to healthy controls (Mann-Whitney-U test) and § = p < 0.05; §§§ = p < 0.001: T1, T2 compared 
to T0 (Wilcoxon test).Respiratory Research 2007, 8:55 http://respiratory-research.com/content/8/1/55
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May-Grünwald solution, followed by 10 min in Giemsa
solution and final rinsing with water).
Lipid and protein analysis
Lipids were extracted from BALF with chloroform/metha-
nol, and phospholipid content was determined by spec-
trophotometric measurement as previously described [6].
Total proteins were analyzed using a commercial assay
(BCA assay, Pierce, Bonn, Germany).
Phospholipid classes were separated by means of high
performance thin-layer chromatography (HPTLC), with
subsequent selective staining and densitometric scanning
as described previously [6]. The profile of molecular spe-
cies of phosphatidylcholine from large surfactant aggre-
gates was analyzed after phospholipolytic cleavage of the
polar headgroup with phospholipase C and conversion of
the resulting diradylglyceroles (DRG) to naphthyl-
urethanes by means of high performance liquid chroma-
tography (HPLC) following a variation of the method
described by Rüstow et al. [28]. Due to a lack of material,
PC molecular species were only calculated in 10 out of 15
patients.
Surfactant proteins were analyzed in large surfactant
aggregates (SP-A, SP-B, SP-C) or in BALF (SP-D): Sur-
factant protein A (SP-A) was measured using an ELISA
protocol as originally described [6]. Surfactant protein B
(SP-B) was quantified by an ELISA method as described by
this group [29] using a monoclonal antibody directed
against porcine SP-B with cross reactivity towards human
SP-B and human SP-B as standard. Surfactant protein C
(SP-C) was determined by means of an ELISA technique
recently described [7], using a polyclonal antibody
directed against human recombinant SP-C and human
recombinant SP-C as standard. SP-D was measured using
a sandwich ELISA with two monoclonal antibodies (IE11,
VIF11-Biotin, Bachem, Heidelberg, Germany) and human
SP-D as standard, as described previously [30].
Isolation of large surfactant aggregates and surface 
tension measurements
Frozen aliquots of BALF were thawn and then centrifuged
(48 000 × g, 1 h, 4°C), separating large and small sur-
factant aggregates [5,31]. The pellet was resuspended in a
small volume of 0.15 M (m/v) NaCl/3 mM CaCl2, and
assessed for PL content. The pellets were then adjusted to
a concentration of 2 mg/ml PL, vortexed for 1 min, and
used for surface tension measurement, which was per-
formed with a pulsating bubble surfactometer (Elec-
tronetics, New York, NJ, USA) as previously described
[32,9]. The surface tension after 5 min of film oscillation
at minimum bubble radius (γ min) and after 11 s film
adsorption (γ ads) is given. Due to the limited amount of
large surfactant aggregates, complete data sets of surface
tension values (T0, T1 and T2) were only measured in six
patients.
Statistical analysis
All data are given as mean ± standard error. Statistical
analysis of differences between i) patients and healthy
controls and between ii) surviving and non-surviving
patients was performed by testing principle significance
diversity first (Kruskal-Wallis-H test), followed by com-
parison with a non-parametric test (Mann-Whitney-U
test). Patient values significantly different from control are
indicated with: * = p < 0.05, ** = p < 0.01, *** = p <
0.001. Values significantly different between surviving
and non-surviving patients are indicated with: # = p <
0.05, ## = p < 0.01, ### = p < 0.001. Statistical analysis of
differences between T0 and T1/T2 values were analyzed
with Wilcoxon's matched-pairs signed-ranks test. Patient
values different from T0 values are indicated with: § = p <
0.05, §§ = p < 0.01, §§§ = p < 0.001.
Results
Clinical and basic BALF data
As summarized in Table 1, the patient cohort exhibited
severe limitation in gas exchange at the time of the first
BAL (T0), with a PaO2/FiO2 ratio of 127.8 ± 10.5 mm Hg.
Values progressively improved during the following eight
days, but remained markedly decreased when compared
to control values at T2 (Table 1). At the time of the first
BAL (T0), patients were ventilated with an average PEEP of
8.4 ± 0.8 cm H2O and a PIP of 24.9 ± 1.3 cm H2O. The
tidal volume was 9.4 ± 0.8 ml/kg bodyweight, and the
APACHE II scores ranged at 19.2 ± 2.2 at the time of the
first BAL (Table 1). Both the described ventilator settings
and the APACHE II scores did not change significantly
during the observation period compared to the initial
time point. Six of the 15 patients died within 28 days and
the average ventilator-free days accounted for 1.6 ± 1.4
days.
The recovery of the BALF was approximately 20% lower in
patients compared to controls and did not change during
the observation period (Table 1). In the BALF obtained at
T0, neutrophils were the predominant cell type in the cell
differential. Later in the time-course, alveolar macro-
phages gradually increased and neutrophils declined
(Table 1). At T2, however, the cell differential was yet not
normalized compared to controls (Table 1). Similarly, a
marked protein load of the alveolar compartment was
encountered at T0 that gradually resolved during the fol-
lowing 8 days. However, at T2, protein concentration in
BALF remained five-fold elevated, compared to healthy
controls (Table 1).Respiratory Research 2007, 8:55 http://respiratory-research.com/content/8/1/55
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Early changes in surfactant properties
At T0 and thus ~12 h after intubation, severe and highly
significant alterations to the surfactant system were
encountered, with a ten-fold reduced phospholipid-to-
protein ratio (Table 2), a large reduction in the relative
amount of large surfactant aggregates (LA, Figure 1), a
pronounced disturbance to the phospholipid and PC
molecular species profile (Table 2) and a significant loss
of all surfactant proteins (Table 2). In view of the phos-
pholipid and PC molecular species profile, significant
reductions in PC and phosphatidylglycerol (PG) were
observed with a concomitant increase in the proportion of
phosphatidylserine (PS), phosphatidylinositol (PI), phos-
phatidylethanolamine (PE) and sphingomyelin (SPH).
Within the PC fraction of the LA, a dramatic reduction in
dipalmitoylated PC species (DPPC), down to less then
half of what was measured in healthy controls was
observed, and was paralleled by a marked increase in
unsaturated species (most of all 16:0/18:1 and 16:0/18:2,
Table 2). The hydrophobic surfactant proteins SP-B and
SP-C as well as SP-A, but not SP-D, were found to be sig-
nificantly reduced (Table 2). As a result, the surface ten-
sion after 11 sec film adsorption (γ ads) and after 5 min of
Table 2: Total phospholipids and surfactant apoprotein concentration, phospholipid profiles, phosphatidylcholine molecular species, 
and adsorption properties of LA§
ARDS Control
T0 (<24 h) T1 (3–5 d) T2 (7–9 d)
Total Phospholipids 
[µg/ml]
31.9 ± 5.0 24.3 ± 4.2 27.9 ± 5.1 35.9 ± 4.8
Phospholipid-to-protein 
ratio
0.043 ± 0.010 *** 0.052 ± 0.021 0.109 ± 0.024 §§ 0.461 ± 0.030
PC [%] 73.3 ± 2.0 ** 72.4 ± 3.6 74.7 ± 2.2 81.3 ± 1.6
PG [%] 3.6 ± 0.9 *** 2.8 ± 0.8 5.3 ± 0.7 § 11.6 ± 1.1
PS [%] 6.5 ± 1.1 *** 5.4 ± 0.9 6.1 ± 1.2 1.8 ± 0.7
PI [%] 5.3 ± 0.9 * 5.3 ± 1.2 5.9 ± 1.3 2.5 ± 0.3
PE [%] 4.8 ± 1.0 * 6.9 ± 1.6 3.3 ± 0.8 1.4 ± 0.4
SPH [%] 5.0 ± 0.7 *** 5.6 ± 0.9 2.9 ± 0.7 § 0.6 ± 0.3
PC 16:0/16:0 26.81 ± 1.61 *** 32.98 ± 2.36 § 40.16 ± 1.89 §§§ 60.65 ± 1.27
PC 16:0/18:1 20.43 ± 1.71 *** 15.37 ± 2.06 § 12.57 ± 0.79 §§ 9.68 ± 0.49
PC 16:0/18:2 10.33 ± 0.80 *** 10.00 ± 1.49 8.53 ± 0.55 § 5.43 ± 0.31
PC 16:0/16:1 7.76 ± 0.53 * 6.46 ± 0.40 § 9.79 ± 0.80 § 4.84 ± 0.55
PC 16:0/14:0 6.76 ± 1.50 6.39 ± 0.51 7.67 ± 1.44 7.18 ± 0.64
PC 16:0/20:4 4.36 ± 0.46 ** 2.63 ± 0.32 § 2.30 ± 0.55 § 1.95 ± 0.19
PC 18:0/18:2 4.52 ± 0.47 * 3.99 ± 0.39 2.98 ± 0.45 § 1.54 ± 0.45
PC 18:1/18/1 4.00 ± 0.23 3.70 ± 0.61 2.52 ± 0.22 § 3.22 ± 0.39
PC 18:0/18:1 2.67 ± 0.37 3.66 ± 0.52 § 2.02 ± 0.18 2.14 ± 0.29
SP-A [% PL] 2.61 ± 0.32 ** 3.07 ± 0.57 3.61 ± 0.27 § 4.12 ± 0.09
SP-B [% PL] 2.29 ± 0.32 ** 2.93 ± 0.43 2.94 ± 0.41 3.71 ± 0.32
SP-C [% PL] 1.19 ± 0.25 * 1.34 ± 0.23 1.37 ± 0.26 2.28 ± 0.22
SP-D [ng/ml] 14.9 ± 2.9 18.8 ± 7.1 18.4 ± 5.8 14.2 ± 2.2
γ ads [mN/m] 39.0 ± 1.3 33.8 ± 4.7 33.2 ± 3.7 19.1 ± 0.9
§ All data represent mean ± standard error. Control = healthy volunteers; ARDS = acute respiratory distress syndrome. Phospholipid-to-protein 
ratio and phospholipid profiles were determined in bronchoalveolar lavage fluids (BALF). Each phospholipid class is depicted as percent of all 
phospholipids. All data are given as mean ± standard error. Definitions of abbreviations: PC = phosphatidylcholine; PG = phosphatidylglycerol; PS = 
phosphatidylserine; PI = phosphatidylinositol; PE = phosphatidylethanolamine; SPH = sphingomyelin. Values for lysophosphatidylcholine and 
cardiolipin were not given due to their low content in patients and controls. Phosphatidylcholine molecular species were determined in large 
surfactant aggregates (LA). Each molecular species is depicted as percent (mol/mol) of all molecular species. Molecular species with a relative 
content lower than 2% (14:0/14:0, 18:0/18:0, 16:0/22:6, 18:0/20:4, 18:1/18:2, 18:0/14:0) are not given. No significant statistical difference in these 
molecular species between ARDS at T0 and healthy controls and ARDS at T0 and T1 or T2, respectively, was observed. All data are given as mean 
± standard error. Definitions of abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = stearic acid; 18:1 = oleic acid; 
18:2 = linoleic acid; 20:4 = arachidonic acid. Surfactant apoproteins SP-A, SP-B and SP-C were determined in large surfactant aggregates and were 
depicted as percent (w/w) of phospholipids. Surfactant apoprotein D was determined in bronchoalveolar lavage fluid (BALF) and is given in ng/ml. 
Surface tension of LA after 11 sec film adsorption (γ ads) is given in mN/m. * = p < 0.05; ** = p < 0.01; *** = p < 0.001: T0 compared to healthy 
controls (Mann-Whitney-U test) and § = p < 0.05; §§ = p < 0.01; §§§ = p < 0.001: T1, T2 compared to T0 (Wilcoxon test).Respiratory Research 2007, 8:55 http://respiratory-research.com/content/8/1/55
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film oscillation at minimum bubble radius (γ min) was
dramatically increased (Table 2, Figure 2).
Time course of surfactant changes
In general, a modest improvement in surfactant composi-
tion and function was encountered at T1, and – even more
evident – at T2. In detail, the relative content of large sur-
factant aggregates significantly increased at T1 and T2
(Figure 1). The phospholipid profile improved especially
in view of phosphatidylglycerol (Table 2) and analysis of
the molecular species of PC indicated a clear and highly
significant increase in the extent of dipalmitoylation,
although the values were clearly below the control range
(Table 2). Correspondingly, the relative amount of PC
molecular species with unsaturated fatty acids diminished
over time (Table 2). The relative amount (compared to
PL) of SP-A, SP-B and SP-C in large surfactant aggregates
increased and – especially in case of SP-A – normal values
were observed at T2. As a result, the surface tension-reduc-
ing properties significantly improved over time, although
markedly elevated γ min and γ ads values were still
observed (Figure 2).
Differences between surviving and non-surviving patients/
Outcome analysis
To investigate a potential role for surfactant measure-
ments as outcome parameter, biochemical and biophysi-
cal surfactant characteristics as well as clinical parameter
were analysed in surviving (SURV) and non-surviving
(non-SURV) patients and significant differences were
observed between these groups. Throughout the observa-
tion period, APACHE II scores were significantly lower in
surviving patients compared to non-surviving patients
(T0: SURV 16.3 ± 1.5; non-SURV: 25.8 ± 2.5; p < 0.01; T2:
SURV: 17.0 ± 1.2; non-SURV: 24.5 ± 1.9; p < 0.01). Con-
cerning clinical data, the PaO2/FiO2 was not different at
T0, but was significantly different at T2 between survivors
(221 ± 17 mmHg) and non-survivors (173 ± 24 mmHg; p
Minimum surface tension Figure 2
Minimum surface tension. The surface tension of large sur-
factant aggregates after 5 min film oscillation at minimum 
bubble radius (γ min) is given. All data are given as mean ± 
standard error. *** = p < 0.001: T0 compared to healthy 
controls (Mann-Whitney-U test); § = p < 0.05; §§ = p < 0.01: 
T2 compared to T0 (Wilcoxon test); # = p < 0.05: non-survi-
vors compared to survivors (Mann-Whitney-U test). Due to 
the limited amount of large surfactant aggregates, complete 
data sets of surface tension values (T0, T1 and T2) were only 
measured in 6 patients (3 survivors, 3 non-survivors).
Relative content of large surfactant aggregates (in percent  (w/w) in total BALF phospholipids) Figure 1
Relative content of large surfactant aggregates (in percent 
(w/w) in total BALF phospholipids). All data are given as 
mean ± standard error. *** = p < 0.001: T0 compared to 
healthy controls (Mann-Whitney-U test); § = p < 0.05; §§ = p 
< 0.01: T2 compared to T0 (Wilcoxon test); # = p < 0.05: 
non-survivors compared to survivors (Mann-Whitney-U 
test).Respiratory Research 2007, 8:55 http://respiratory-research.com/content/8/1/55
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< 0.05). PEEP and PIP values were not different between
surviving and non-surviving patients. Tidal volumes were
significantly higher in non-surviving patients at T0, but
not at T1 and T2 (T0: SURV 8.3 ± 0.4 ml/kg bw; non-
SURV: 12.3 ± 1.1 ml/kg bw; p < 0.01; T2: SURV 8.4 ± 0.3
ml/kg bw; non-SURV: 9.8 ± 1.3 ml/kg bw). The relative
neutrophil counts were not significantly different at T0
and T1, but were significantly lower at T2 in surviving
patients (SURV 17.1 ± 3.9; non-SURV: 29.8 ± 4.2; p <
0.05).
The relative content of large surfactant aggregates was sig-
nificantly lower in non-surviving patients (Figure 1). The
relative content of phosphatidylglycerol was lower in
non-surviving patients throughout the observation
period, however, this decrease was not significant. No sig-
nificant differences between surviving and non-surviving
patients were found in the phosphatidylcholine molecu-
lar species profile and in relative content of SP-A, SP-B and
SP-D. SP-C levels in large surfactant aggregates at T2 were
significantly lower in non-survivors compared to surviv-
ing patients (T2: SURV 0.67 ± 0.05% of PL; non-SURV:
0.37 ± 0.06% of PL; p < 0.01). The values for minimum
surface tension (γ min) of large surfactant aggregates were
significantly lower in surviving patients compared to non-
survivors (Figure 2).
Correlational analysis
Pearson correlation was performed between (A) sur-
factant compositional and functional parameters and
PaO2/FiO2, and (B) between surfactant components and
minimum surface tension of the surfactant isolates. Pear-
son correlation coefficients, r, and statistical significance
levels, p, are given in Table 3. All correlations between sur-
factant parameters and PaO2/FiO2 were significant (p <
0.05), with the exception of the total protein correlation.
The highest correlation was observed for minimum sur-
face tension, phospholipid-to-protein ratio, SP-C, SP-A
and DPPC in LA (Figure 3, Table 3). With respect to the
correlation between surfactant parameters and minimum
surface tension, the highest correlation was found for
DPPC in LA and SP-B in BALF (Table 3).
Discussion
The aim of the current study was to investigate the time
course of surfactant changes in patients with direct ARDS
due to pneumonia or aspiration, a patient group that has
recently been shown to be different from indirect ARDS
patients with respect to imaging analysis, lung elasticity,
recruitment capacity and frequency of additional organ
failure, compared to ARDS patients with an extrapulmo-
nary trigger event (indirect ARDS) [33,34,17]. As the fre-
quency of additional organ failure has been linked to the
outcome of ARDS patients [35], patients with direct ARDS
may also have a slightly better prognosis. Considering
these data, we focused on patients with direct ARDS. Serial
bronchoalveolar lavages were performed at an early, inter-
mediate and later stage of the disease and analyzed for
lipid and protein composition and for surface properties
of pulmonary surfactant. In accordance with previous
reports [3-6], severe alterations of the pulmonary sur-
factant system were encountered in early direct ARDS,
both, when being compared to the herein described group
of healthy non-ventilated individuals or to a previously
studied group of mechanically ventilated patients with
cardiogenic lung edema reflecting a kind of ventilated
control group in absence of significant inflammatory lung
disease [6]. A considerable improvement in surfactant
composition and function was noted over time, with
some parameters reaching the normal range (such as SP-
A, SP-B and large surfactant aggregate content), while oth-
ers still remained different from controls (such as e.g.
extent of phosphatidylcholine dipalmitoylation) at T2.
Notably, the minimum surface tension of the isolated
large surfactant aggregate fraction, although significantly
improved over time, ranged at ~13 mN/m at T2, and thus
was still highly elevated compared to healthy controls (~1
mN/m). Between T0 and T2, a highly significant correla-
Table 3: Correlational analysis of ARDS data (T0 – T2)§
rp
(A)
PaO2/FiO2 vs. γ min -0.831 < 0.001
PaO2/FiO2 vs. phospholipid-to-protein ratio 0.662 < 0.001
PaO2/FiO2 vs. SP-C 0.644 < 0.001
PaO2/FiO2 vs. SP-A 0.627 < 0.001
PaO2/FiO2 vs. DPPC in LA 0.590 0.003
PaO2/FiO2 vs. phosphatidylglycerol 0.538 < 0.001
PaO2/FiO2 vs. neutrophils -0.370 0.02
PaO2/FiO2 vs. SP-B 0.448 0.003
PaO2/FiO2 vs. total BALF protein -0.238 0.12
(B)
γ min vs. DPPC in LA -0.754 0.012
γ min vs. SP-B -0.708 0.002
γ min vs. total protein 0.641 0.007
γ min vs. SP-A -0.598 0.02
γ min vs. neutrophils 0.553 0.05
γ min vs. phospholipid-to-protein ratio -0.510 0.04
γ min vs. SP-C 0.281 0.29
γ min vs. phosphatidylglycerol 0.008 0.98
§ Pearson correlation was performed between (A) surfactant 
compositional and functional parameters and PaO2/FiO2 and (B) 
between surfactant components and minimum surface tension (γ min) 
of the surfactant isolates for ARDS patients at T0, T1 and T2. The 
Pearson correlation coefficient, r, and the statistical significance, p, is 
given.Respiratory Research 2007, 8:55 http://respiratory-research.com/content/8/1/55
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tion between gas exchange data and surfactant properties
was encountered. The extent of surfactant improvement
was significantly higher in survivors as compared to non-
survivors.
To our best knowledge, only limited and conflicting data
exist with regard to surfactant properties during the time
course of ARDS. In an early study, Pison et al. [4] investi-
gated pulmonary surfactant in a cohort of patients with
ARDS after multiple trauma. In contrast to our study,
these authors found a progressive deterioration of sur-
factant properties in the majority of parameters investi-
gated. For example, total BALF protein remained
unchanged during the first seven days of the disease in
patients with high ARDS score, and the relative content of
phosphatidylcholine declined significantly between day 0
and day 14. The reason for the discrepancy with our data
is currently unclear, but differences in the triggering event
(indirect in their study versus direct ARDS in our study)
may play a role. Greene et al. [24] analyzed surfactant-
associated proteins SP-A, SP-B and SP-D in patients at risk
for ARDS, and during the time course of ARDS of unspec-
ified etiology. In line with our data, they found decreased
SP-A and SP-B levels compared to controls, but SP-A
remained consistently low during the observation period
(14 days). Another study [36] investigated serial changes
in phospholipid composition in ARDS and found that
phospholipid properties are partially improved during the
time course in moderate and mild respiratory failure, but
not in severe respiratory failure. Nakos et al. [37] investi-
gated surfactant changes 0, 3 and 6 days after onset of
ARDS. In accordance to our data, a decrease in lavagable
proteins and improvements of the BALF cellular profile
over time was visible. Additionally, PaO2/FiO2  values
increased from 120 mm Hg (early ARDS) to 180 mm Hg
(late ARDS). In contrast to our study, however, no
improvement in the profile of phospholipid classes was
found throughout the observation period, and total phos-
pholipids decreased between 0 and 6 days.
In view of our data we suggest that dipalmitoylated phos-
phatidylcholine (DPPC), SP-B and SP-C are the probably
most informative surfactant compounds that may explain
the incomplete recovery of surface activity of the LA frac-
tion after 7–9 days of ventilation. DPPC was reduced to
less than 50% of control values at T0 and reached only
~65% of control values at T2. The reason for this pro-
found and persistent reduction is currently unclear. Con-
tamination with non-surfactant phospholipids, in our
opinion, does not play a major role, because the analysis
was performed with isolated large surfactant aggregates,
which represent freshly secreted surfactant material. This
assumption is further supported by the observation of a
superimposable molecular species pattern of PC from LA
being either prepared by means of sodium bromide gradi-
ent centrifugation according to Shelley et al. [38] or by
means of high speed centrifugation at 48 000 × g (data not
given in detail). We suggest that disturbances in surfactant
phosphatidylcholine metabolism, for example, distur-
bances in the deacylation-reacylation pathway ("remode-
ling") [39,40] are largely responsible for this persistent
depression of DPPC levels in BALF. However, further
experiments are needed to clarify this issue. In addition,
the hydrophobic surfactant proteins, which are known to
dramatically enhance film stability under compression
and adsorption facilities, were reduced to ~50% of con-
trols, and only partially recovered during the later time
course. It has also to be noted that our currently applied
technique for measurement of SP-B and SP-C does not
allow for the differentiation between intact mature SP-B/
C and degradation products of these proteins, the genera-
tion of which may additionally exert a detrimental effect
on surface activity of the LA fraction. Likewise, the under-
lying reason for the persistent suppression of the hydro-
phobic surfactant proteins despite full recovery of SP-A
and unchanged SP-D values is currently unclear.
The study is limited in that only a few of the ARDS
patients studied herein were mechanically ventilated in
full accordance with the low-stretch strategy. Unfortu-
nately, the vast majority of patients had already been
recruited into this study before mechanical ventilation
with low tidal volumes has been recognized as an impor-
tant strategy to decrease mortality and before low-stretch
ventilation has been applied routinely to ARDS patients.
Therefore, we can not completely exclude that the time
Correlation between the minimum surface tension of the  surfactant isolates (γ min) and the PaO2/FiO2 ratio (mean  oxygen tension in arterial blood/inspiratory oxygen fraction)  in ARDS patients at T0, T1 and T2 Figure 3
Correlation between the minimum surface tension of the 
surfactant isolates (γ min) and the PaO2/FiO2 ratio (mean 
oxygen tension in arterial blood/inspiratory oxygen fraction) 
in ARDS patients at T0, T1 and T2. The Pearson correlation 
coefficient r is given. Due to the limited amount of large sur-
factant aggregates, complete data sets of surface tension val-
ues (T0, T1 and T2) were only measured in six patients.Respiratory Research 2007, 8:55 http://respiratory-research.com/content/8/1/55
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course of surfactant alterations may be different in ARDS
patients treated with low tidal volumes.
An interesting aspect of the study is the observation that
non-surviving patients displayed more unfavourable sur-
factant changes as compared to survivors who seemed to
recover more quickly. This may suggest a causal associa-
tion between surfactant function and outcome. However,
it has to be taken into consideration that non-survivors
were, at least at T0, ventilated with significantly higher
lung volumes as compared to survivors. In line with the
proposed relationship the herein described, more severe,
surfactant changes in the non-survivor group may have
induced the use of a more aggressive ventilatory approach.
On the other hand it is well known, that ventilation with
high tidal volumes may result in alterations of the pulmo-
nary surfactant system [41]. Therefore, it is also imagina-
ble that higher tidal volumes are the underlying
mechanism for the observed more impaired surfactant
function in the non-survivors and may in this way con-
tribute to poorer outcome. Eventually, it is possible that
higher tidal volumes in non-survivors may explain the dif-
ferences in outcomes independent of surfactant function.
Do the data we present here help us to better understand
the results of previous clinical trials, and to improve the
design of future trials focusing on surfactant treatment in
ARDS?
Aside from some smaller phase II studies employing nat-
ural surfactant preparations [18,19,22] three larger rand-
omized, double-blind, placebo controlled, phase III trials
using synthetic (Exosurf [42]) or recombinant SP-C based
(Venticute [17]) surfactant preparations have yet been
published. In the Exosurf trial, a fully synthetic phosphol-
ipid mixture containing tyloxapol was administered via
continuous aerosolization to ARDS patients over a time
period of 5 days. Neither gas exchange nor survival was
different between placebo and verum groups [42] and this
has been attributed to the overall much too low dose (~5
mg/kg body weight of phospholipids per day) being
applied, and the high sensitivity of Exosurf towards inhi-
bition. In contrast, a significant improvement in gas
exchange was encountered in the two phase III studies
assessing Venticute in ARDS patients [17] in the first 24 h
after surfactant treatment, but not after 24 h. 46% of these
patients had direct lung injury due to aspiration or pneu-
monia, and Venticute was administered up to four times
at a dose of 50 mg/kg body weight phospholipids within
the first 24 h. No additional treatment was performed
after 24 h. Despite the beneficial effect on gas exchange,
28 d mortality was the same in the verum and the placebo
group.
Considering the data that we present here, it seems rea-
sonable to speculate that the duration of treatment in the
Venticute trials was not long enough to ascertain an
enduring effect of surfactant treatment on gas exchange,
although there is only limited information available with
regard to surfactant properties in response to surfactant
treatment. As outlined in one recent investigation in sur-
factant treated ARDS patients, application of up to 500
mg/kg body weight of a calf lung surfactant extract in the
first 24 h did not result in a persistent improvement of
minimum surface tension values 72 h after the start of
treatment (γ min value of ~15 mN/m) [21]. Even if the
initial PaO2/FiO2 ratio has failed to show a predictive
value in ARDS patients, it has been shown that missing
improvement in pulmonary function during the first week
indicates worse outcome. Thus, persistent improvement in
oxygenation, along with the possibility to de-escalate the
ventilatory regimen, may indeed promote better outcome
in ARDS. In this line of reasoning, multiple surfactant dos-
ing with persistent improvement in gas exchange may
ultimately improve outcome in ARDS.
Conclusion
We conclude that severe disturbances to surfactant com-
position and function occur early in direct ARDS due to
pneumonia or aspiration, which only gradually resolve in
the further time course of 8 days. These disturbances
mostly affect the essential phospholipids dipalmitoylated
phosphatidylcholine and phosphatidylglycerol and the
surfactant-associated proteins SP-A, SP-B and SP-C. Corre-
lational analysis suggests that the reduction of DPPC has
the most significant association with the surfactant func-
tion impairment. These results may have impact on future
strategies for surfactant therapy regarding the optimal
composition and duration of surfactant administration.
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